What is Alfa Laval - Pharmaceutical Solutions's cybersecurity risk score?

Alfa Laval - Pharmaceutical Solutions has an AI-generated cybersecurity risk score of 754 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has Alfa Laval - Pharmaceutical Solutions experienced?

According to Rankiteo, Alfa Laval - Pharmaceutical Solutions currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Alfa Laval - Pharmaceutical Solutions been affected by any supply chain cyber incidents ?

According to Rankiteo, Alfa Laval - Pharmaceutical Solutions has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Alfa Laval - Pharmaceutical Solutions have SOC 2 Type 1 certification ?

According to Rankiteo, Alfa Laval - Pharmaceutical Solutions is not certified under SOC 2 Type 1.

Does Alfa Laval - Pharmaceutical Solutions have SOC 2 Type 2 certification ?

According to Rankiteo, Alfa Laval - Pharmaceutical Solutions does not hold a SOC 2 Type 2 certification.

Does Alfa Laval - Pharmaceutical Solutions comply with GDPR ?

According to Rankiteo, Alfa Laval - Pharmaceutical Solutions is not listed as GDPR compliant.

Does Alfa Laval - Pharmaceutical Solutions have PCI DSS certification ?

According to Rankiteo, Alfa Laval - Pharmaceutical Solutions does not currently maintain PCI DSS compliance.

Does Alfa Laval - Pharmaceutical Solutions comply with HIPAA ?

According to Rankiteo, Alfa Laval - Pharmaceutical Solutions is not compliant with HIPAA regulations.

Does Alfa Laval - Pharmaceutical Solutions have ISO 27001 certification ?

According to Rankiteo,Alfa Laval - Pharmaceutical Solutions is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Alfa Laval - Pharmaceutical Solutions operate in ?

Alfa Laval - Pharmaceutical Solutions operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Alfa Laval - Pharmaceutical Solutions have ?

Alfa Laval - Pharmaceutical Solutions employs approximately None employees people worldwide.

Does Alfa Laval - Pharmaceutical Solutions own any subsidiaries ?

Alfa Laval - Pharmaceutical Solutions presently has no subsidiaries across any sectors.

How many LinkedIn followers does Alfa Laval - Pharmaceutical Solutions have ?

Alfa Laval - Pharmaceutical Solutions's official LinkedIn profile has approximately 4,198 followers.

What is the NAICS classification code for Alfa Laval - Pharmaceutical Solutions ?

Alfa Laval - Pharmaceutical Solutions is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Alfa Laval - Pharmaceutical Solutions have a Crunchbase profile ?

No, Alfa Laval - Pharmaceutical Solutions does not have a profile on Crunchbase.

Does Alfa Laval - Pharmaceutical Solutions have a LinkedIn profile ?

Yes, Alfa Laval - Pharmaceutical Solutions maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/alfa-laval-pharmaceutical-and-biotechnology-solutions.

How many cybersecurity incidents has Alfa Laval - Pharmaceutical Solutions experienced ?

As of June 30, 2026, Rankiteo reports that Alfa Laval - Pharmaceutical Solutions has not experienced any cybersecurity incidents.

How many peer or competitor companies does Alfa Laval - Pharmaceutical Solutions have ?

Alfa Laval - Pharmaceutical Solutions has an estimated 5,696 peer or competitor companies worldwide.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

ALPS

Boost Score +25 with badge (5 left)

754

/1000

Fair

779

/1000

Fair

Alfa Laval - Pharmaceutical Solutions Vendor Cyber Rating & Cyber Score

alfalaval.com

Add Your Compliance Badge

Alfa Laval has a long-term presence within pharmaceutical and biopharmaceutical processing, built on the accumulated expertise in the company of the past 130 years across nearly 100 countries. The company offers innovative solutions and services with a competitive cost of ownership and timely delivery throughout the product life cycle to optimize customers’ processes. Equipment is tailored with the use of IoT and in line with principles for Industry 4.0 to improve operational efficiency, increase yield and enable incremental sustainable optimization. Comprehensive quality documentation offers full transparency into sourcing, production and supply chains to enable regulatory compliance and operation in line with pharmaceutical guidelines

ALPS A.I CyberSecurity Scoring

Scoring History

ALPS

Alfa Laval - Pharmaceutical Solutions CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

No data available

Loading…

A.I.

ALPS Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for ALPS

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Alfa Laval - Pharmaceutical Solutions in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Alfa Laval - Pharmaceutical Solutions in 2026.

Incident Types ALPS vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Alfa Laval - Pharmaceutical Solutions in 2026.

Incident History - ALPS (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Alfa Laval - Pharmaceutical Solutions Subsidiaries

ALPS

Pharmaceutical Manufacturing

Website: https://www.alfalaval.com/industries/biotech-pharmaceuticals/biotechnology/?utm_source=linkedin&utm_medium=social&utm_content=linkedintagline_biopharma&utm_campaign=pharma

Company Size: 10,001+ employees

Alfa LavalIndustrial Machinery Manufacturing

Alfa Laval - EnergyTillverkning av industriella maskiner

Alfa Laval - Marine solutionsSjöfart

FramoIndustrial Machinery Manufacturing

Alfa Laval - Food & Beverage ProductionMat- och dryckesservering

Loading…

Alfa Laval - Pharmaceutical Solutions Similar Companies

Takeda

cb takeda.com

We strive to transform lives. While the science we advance is constantly evolving, our core purpose is enduring. For more than two centuries, our values have guided us to do what’s right for patients and for society. We know that changing lives requires us to do things differently. We start by listening to and addressing what really matters to patients, the people who love them, and those in the healthcare system who provide care. And that’s what inspires us all to be bold, push boundaries and set new standards that open up greater opportunities. Read our community guidelines: https://takeda.info/communityguidelines

AbbVie

cb abbvie.com

AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, aesthetics and other areas of unmet need. Learn more about us at www.abbvie.com and review our community guidelines at https://www.abbvie.com/social-media-community-guidelines.html.

UCB

cb ucb.com

At UCB, we believe everyone deserves to live the best life they can - as free as possible from the challenges and uncertainty of disease. Our purpose is to support people living with severe central nervous system and immunological conditions by delivering meaningful solutions that go beyond medicine. We are driven by the experiences of patients and caregivers, and inspired to pursue innovations that create real value - not just in clinical outcomes, but in everyday moments, dreams pursued, and simple pleasures enjoyed. Our ambition is to unlock transformative science and technologies that respond to unmet needs and elevate lives. From our headquarters in Belgium to nearly 40 countries around the world, we nurture a culture of respect and care. By listening deeply and collaborating across borders and disciplines, we enable cutting-edge research shaped by patients’ needs. Through strong connections with healthcare professionals, partners, and communities, we strive to make a lasting impact - today and into the future. We're inspired by patients, driven by science.

Alkem Laboratories Ltd.

alkemlabs.com

A single idea, which sprouts from a human mind, contains the potential to create marvels that can influence generations. It can redefine rules, it can transform the world. Back in the year 1973, a team of individuals came with such an idea – The idea called Alkem. It was highly potent and resilient, like a spark that could ignite a thousand more ideas. And it did! Looking back at our 4 decade, illustrious journey, that one small idea has Not only triggered us to become one of India’s largest generic and specialty pharmaceutical company but also, create a foothold in over 50 countries 32% of our revenue is generated via offshore sales. As well as we have consistently been ranked amongst the top ten pharmaceutical companies in India. Our portfolio includes illustrious brands like Clavam, Pan, Pan-D and Taxim-O, which feature amongst top 50 pharmaceutical brands in India. For over a decade, our dominance in anti-infective segment has remained unchallenged. We have 21 manufacturing facilities at multiple locations in India and the United States of America. Our upper-crest facilities are inspected and audited as per cGMP guidelines as laid down by leading regulatory authorities such as USFDA, MHRA - UK, SAHPRA-South Africa, TGA - Australia, ANVISA - Brazil, WHO - Geneva, TPD - Health Canada, PPB - Kenya, NDA - Uganda, MOH - Sudan, INVIMA - Colombia, TFDA - Tanzania, Zimbabwe, BfArM-Germany & Other Africa, Asian & CIS Countries. Another feather in our cap was added on December 23rd, 2015, when, Alkem completed it's Initial Public Offering (IPO) and was listed on the Bombay Stock Exchange Limited and the National Stock Exchange of India Limited. Although passion is the fuel that keeps ideas alive, innovation is the catalyst that gives it flight! With over 500 scientists working in 5 global R&D centers, we are empowering innovations that align with our philosophy of ‘Extended Lifecare Beyond Boundaries’.

Glenmark Pharmaceuticals

glenmarkpharma.com

Glenmark Pharmaceuticals Limited is a research-led, global organization committed to enriching lives. Innovation is deeply embedded in Glenmark’s culture; it is how we differentiate ourselves in our key markets and create greater value for our stakeholders. In our journey of innovation over the past four and a half decades, we have evolved from a generics company to a global organization offering specialty and branded products. Glenmark’s core values of Achievement, Respect, and Knowledge impart a sense of organizational unity that drives our growth. We have established a robust global branded generics, specialty, and OTC business; with a significant presence in the therapy areas of dermatology, respiratory, and oncology. Our ten state-of-the-art manufacturing facilities spread across four continents with operations in over 80 countries help us impact millions of patients across the globe. We recently consolidated our innovation efforts in small molecules and biologics research with the formation of ‘Ichnos Glenmark Innovation’ (IGI). This alliance is aimed at leveraging the capabilities of Glenmark and its subsidiary, Ichnos Sciences, to accelerate innovation in cancer treatment. To know more about IGI, check out: https://iginnovate.com/ Sustainability is an integral aspect of all our operations and we are focused on achieving our Environment, Social and Governance (ESG) goals. Our responsibility also extends to our communities, and over the years, our CSR efforts have touched the lives of over 3 million people.

Sanofi

sanofi.com

We are an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Interactions with this account must comply with the Terms: https://bit.ly/sanofi-terms

Astellas Pharma

astellas.com

Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need. Visit our Global Astellas LinkedIn Community Guidelines to learn more about interacting with this page: https://www.astellas.com/en/global-linkedin-community-guidelines

Cipla

cipla.com

Cipla is a leading global pharmaceutical company trusted by healthcare professionals and patients across the world since 1935. A compassionate approach to healthcare that goes beyond the pursuit of profit and growth has been the force impelling Cipla’s history over the years. Our credo and our purpose of ‘Caring for Life' continues to guide our actions towards our people and the planet for creating a sustainable future. Cipla today has presence in 80+ countries, providing over 1,500 products across various therapeutic categories in 50+ dosage forms. Keeping with our legacy of care, we constantly strive to ensure access to high-quality medicines that make a difference in the lives of patients. Our paradigm-changing offer of a triple anti-retroviral (ARV) therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 was pivotal in bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. An unmatched presence across the care continuum (awareness, prevention, diagnosis, treatment and adherence) and the widest range of drug-device combinations has established Cipla’s respiratory leadership in India and other key emerging markets. Armed with this legacy and a deep understanding of the lungs, we have articulated our aspiration to become a global lung leader and help millions breathe free.

Catalent

catalent.com

Championing the missions that matter™. Catalent, Inc. is a leading global contract development and manufacturing organization (CDMO) and trusted partner to pharma, biotech, and consumer health companies worldwide. We put patients first in everything we do, helping people live better and healthier lives through every product we help develop, manufacture and deliver. With over 1,000 active development programs at any given time, we launch over 100 new products and line extensions annually. Catalent has supported half of all FDA approvals over the past decade, and our teams working at over 40 global sites help us produce over 60 billion doses every year. Our strength lies in our people: teams across our more than 40 sites and thousands of passionate scientists and technicians who bring expertise in development sciences, delivery technologies, and multi-modality manufacturing. What unites us is our commitment to championing our partners’ missions as our own, anticipating customer needs, solving complex challenges and ultimately making a difference in the lives of patients across the globe. At Catalent, you will be able to directly have an impact, solving problems and ensuring excellence for our customers. Our focus on delivering meaningful outcomes alongside our customers means your work directly impacts millions of people around the world. Join us in championing the missions that matter. Catalent is headquartered in Tampa, Florida, with over 40 global sites. Visit www.catalent.com to learn more.

Loading…

NEWS

Alfa Laval - Pharmaceutical Solutions CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

July 03, 2025 07:00 AM

Alfa Laval’s AI-Driven Clariot Solution is Purpose-Built for Monitoring Hygienic Process Equipment

Alfa Laval has launched Clariot, an artificial intelligence (AI)-driven solution that monitors the condition of hygienic process equipment.

Read Article

June 19, 2025 07:00 AM

Alfa Laval launches AI-powered condition monitoring

Alfa Laval introduces Clariot™, an AI-based condition monitoring solution designed for hygienic process equipment, providing precise...

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-8023

SUMMARY

Zephyr's HTTP server (subsys/net/lib/http) provides a static-filesystem resource type (HTTP_RESOURCE_TYPE_STATIC_FS, available when CONFIG_FILE_SYSTEM is enabled) that serves files from a configured root directory. Before this fix, both the HTTP/1 and HTTP/2 front-ends placed the raw, attacker-controlled request path into client-url_buffer (assembled in on_url() for HTTP/1 and copied verbatim from the :path pseudo-header for HTTP/2) without resolving ./.. segments. The static-FS handler then built the on-disk filename by directly concatenating the configured root with that raw URL (snprintk(fname, ..., "%s%s", static_fs_detail-fs_path, client-url_buffer) at http_server_http1.c:603 and http_server_http2.c:490) and opened it with fs_open(fname, FS_O_READ). Because the handler is reached via wildcard/leading-dir (fnmatch FNM_LEADING_DIR) or fallback resource matching, a request such as GET /<prefix/../../<file is dispatched to the handler and, after the underlying filesystem (e.g. LittleFS/FAT) resolves the .. segments, escapes the configured web root, letting an unauthenticated remote client read arbitrary readable files on the mounted volume (information disclosure). The HTTP server requires no TLS or authentication to reach this path. The fix adds http_server_remove_dot_segments(), which canonicalizes the path portion of the URL before resource lookup in both protocol handlers, neutralizing the traversal. Affects releases v4.0.0 through v4.4.0 for deployments that register a static-filesystem resource.

Published

Date2026-06-29

Updated

Date2026-06-29

RISK INFORMATION (Score: 7.5)

cvss3

Base Score: 7.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:N/A:N

Impact Score

3.6

Exploitability

3.9

REFERENCES

CVE-2026-7656

SUMMARY

The IPv6 Neighbor Discovery handlers in subsys/net/ip/ipv6_nbr.c (handle_ra_input, handle_ns_input, handle_na_input) used an incorrect boolean expression that combined the RFC 4861 validity checks with the ICMPv6 code check using the wrong operator precedence: the form was '((length/hop/source/target checks) && (icmp_hdr-code != 0))'. Because every legitimate ND message carries ICMPv6 code 0, an attacker setting code == 0 (the normal value) caused the entire predicate to evaluate false, so the packet was never dropped and all of the other checks were silently skipped. The bypassed checks include the mandatory Hop Limit == 255 verification (which proves an ND packet originated on-link and was not forwarded) and, for Router Advertisements, the requirement that the source be a link-local address, as well as multicast-target sanity checks. As a result, an adjacent on-link attacker — and, because the Hop-Limit-255 guard is bypassed, potentially a remote/off-link attacker whose packets would otherwise be rejected — can have forged Router Advertisement, Neighbor Solicitation, and Neighbor Advertisement messages accepted. A forged RA lets the attacker reconfigure the victim's default router, on-link prefixes (SLAAC), MTU, reachable/retransmit timers, and (with CONFIG_NET_IPV6_RA_RDNSS) DNS servers, while forged NS/NA enable neighbor-cache poisoning, enabling man-in-the-middle, traffic redirection, and denial of service. The flaw is an input-validation/authentication weakness rather than a memory-safety issue: the underlying packet-parsing primitives (net_pkt_get_data, net_pkt_read, net_pkt_skip) are independently bounds-safe and the validated 'length' is the true buffer length, so skipping the length check causes no out-of-bounds access. The defect has existed since the logic was introduced in 2018 and shipped in all releases through v4.4.0; it is fixed by splitting the condition so any failing check drops the packet.

Published

Date2026-06-29

Updated

Date2026-06-29

RISK INFORMATION (Score: 8.1)

cvss3

Base Score: 8.1

Complexity: LOW

CVSS:3.1/AV:A/AC:L/PR:N/UI:N/S:U/C:N/I:H/A:H

Impact Score

5.2

Exploitability

2.8

REFERENCES

CVE-2026-51219

SUMMARY

A heap buffer overflow in the HighPriorityASDUQueue_hasUnconfirmedIMessages function of lib60870 v2.3.3 to v2.3.6 allows attackers to cause a Denial of Service (DoS) via a crafted payload.

Published

Date2026-06-29

Updated

Date2026-06-29

RISK INFORMATION (Score: )

Impact Score

Exploitability

REFERENCES

CVE-2026-51218

SUMMARY

A heap buffer overflow in the TS7Worker::PerformFunctionWrite() function (/core/s7_server.cpp) of snap7 v1.4.3 allows attackers to cause a Denial of Service (DoS) via a crafted packet.

Published

Date2026-06-29

Updated

Date2026-06-29

RISK INFORMATION (Score: )

Impact Score

Exploitability

REFERENCES

CVE-2026-10648

SUMMARY

mcumgr_serial_process_frag() in subsys/mgmt/mcumgr/transport/src/serial_util.c calls net_buf_reset() on the result of smp_packet_alloc() before checking it for NULL. smp_packet_alloc() uses net_buf_alloc(K_NO_WAIT) against the shared MCUmgr packet pool (CONFIG_MCUMGR_TRANSPORT_NETBUF_COUNT, default 4), which returns NULL when the pool is exhausted. In default builds the __ASSERT_NO_MSG in net_buf_reset is a no-op, so net_buf_simple_reset writes through the NULL pointer (buf->len = 0; buf->data = buf->__buf), causing a fault/crash. The fragment data reaches this code from attacker-controlled bytes on the MCUmgr serial/UART/shell-console transports (smp_uart.c, smp_raw_uart.c, smp_shell.c), and a fresh buffer is allocated at the start of essentially every new packet. An attacker on the serial/console link can flood the transport to drive the 4-entry buffer pool to exhaustion and induce the NULL dereference, crashing the device (denial of service). The defect was introduced after the original MCUmgr rework and shipped in Zephyr v4.4.0. The fix moves the NULL check ahead of net_buf_reset.

Published

Date2026-06-29

Updated

Date2026-06-29

RISK INFORMATION (Score: 6.2)

cvss3

Base Score: 6.2

Complexity: LOW

CVSS:3.1/AV:L/AC:L/PR:N/UI:N/S:U/C:N/I:N/A:H

Impact Score

3.6

Exploitability

2.5

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…